目的 探讨贝伐珠单抗注射液联合盐酸埃克替尼片治疗中晚期非小细胞肺癌的临床疗效。方法 选取2014年1月—2016年1月武警特色医学中心门诊收治的82例中晚期非小细胞肺癌患者作为研究对象，根据随机区组设计法将患者分为对照组（41例）和治疗组（41例）。对照组口服盐酸埃克替尼片，125 mg/次，3次/d，直到病情进展或出现不可耐受的不良反应时停止。治疗组在对照组治疗的基础上第1天静脉滴注贝伐珠单抗注射液，7.5 mg/kg用0.9%氯化钠100 mL稀释。以21 d为1个化疗周期，两组患者治疗2个化疗周期。观察两组患者的近期疗效，同时比较两组FACT-L 4.0评分、肿瘤标志物水平、毒副作用发生情况和生存情况。结果 治疗后，治疗组的客观缓解率（ORR）和疾病控制率（DCR）分别为41.5%、82.9%，显著高于对照组的29.3%、63.4%，两组近期疗效比较差异具有统计学意义（P<0.05）。治疗后，两组生理状况评分、社交/家庭状况评分、情感状况评分、功能状况评分、肺癌附加关注评分和总分均显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组评分显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组细胞角蛋白19片段（CYFRA21-1）、糖类抗原125（CA125）、血管内皮生长因子（VEGF）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗后治疗组肿瘤标志物水平均显著低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组中位无进展时间（PFS）、中位生存时间（OS）、1年生存率、2年生存率均显著高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 贝伐珠单抗注射液联合盐酸埃克替尼片治疗中晚期非小细胞肺癌疗效显著，可有效提高患者生存率和生活质量，降低血清肿瘤标志物，安全可靠，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Bevacizumab Injection combined with Icotinib Hydrochloride Tablets in treatment of intermediate and advanced non-small cell lung cancer. Methods Patients (82 cases) with intermediate and advanced non-small cell lung cancer in Armed Police Medical Center from January 2014 to January 2016 were randomly divided into the control group (41 cases) and treatment group (41 cases). Patients in the control group were po administered with Icotinib Hydrochloride Tablets, 125 mg/time, three times daily, stopped until the progress or untolerable adverse reaction occurs. Patients in the treatment group were iv administered with Bevacizumab Injection on the basis of the control group at first day, 7.5 mg/kg added into 0.9% NaCl injection 100 mL. One chemotherapy cycle had 21 d, and patients in two groups were treated for 2 cycles. After treatment, the short-term efficacy was evaluated, and FACT-L 4.0 scores, tumor markers levels, toxic and side-effect, and living conditions in two groups were compared. Results After treatment, the ORR and DCR in the treatment group were 41.5% and 82.9%, respectively, which were higher than 29.3% and 63.4%, respectively in the control group, and there was difference between two groups (P<0.05). After treatment, the physiological status, social/family status, emotional status, functional status, additional attention to lung cancer scores and total score in two groups were significantly increased, and the difference was statistically significant in the same group (P <0.05). After treatment, the scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, CYFRA21-1, CA125, and VEGF levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, CYFRA21-1, CA125, and VEGF levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the PFS, OS, 1-year survival rate, and 2-year survival rate in the treatment group were significantly higher than those in the control group, and there was difference between two groups (P<0.05). Conclusion Bevacizumab Injection combined with Icotinib Hydrochloride Tablets has clinical curative effect in treatment of intermediate and advanced non-small cell lung cancer, can effectively improve the survival rate and quality of life of patients, reduce serum tumor markers, safe and reliable, which has a certain clinical application value.